FR17C1009I2 - Agents therapeutiques pour reduire les niveaux d' hormone parathyroidienne - Google Patents

Agents therapeutiques pour reduire les niveaux d' hormone parathyroidienne

Info

Publication number
FR17C1009I2
FR17C1009I2 FR17C1009C FR17C1009C FR17C1009I2 FR 17C1009 I2 FR17C1009 I2 FR 17C1009I2 FR 17C1009 C FR17C1009 C FR 17C1009C FR 17C1009 C FR17C1009 C FR 17C1009C FR 17C1009 I2 FR17C1009 I2 FR 17C1009I2
Authority
FR
France
Prior art keywords
therapeutic agents
parathyroid hormone
hormone levels
reduce parathyroid
reduce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1009C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kai Pharmaceuticals Inc
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43527590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1009(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Publication of FR17C1009I1 publication Critical patent/FR17C1009I1/fr
Application granted granted Critical
Publication of FR17C1009I2 publication Critical patent/FR17C1009I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR17C1009C 2009-07-29 2017-03-17 Agents therapeutiques pour reduire les niveaux d' hormone parathyroidienne Active FR17C1009I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22969509P 2009-07-29 2009-07-29
US25581609P 2009-10-28 2009-10-28
US31363510P 2010-03-12 2010-03-12
PCT/US2010/043792 WO2011014707A2 (fr) 2009-07-29 2010-07-29 Agents thérapeutiques pour réduire les niveaux d’hormone parathyroïdienne

Publications (2)

Publication Number Publication Date
FR17C1009I1 FR17C1009I1 (fr) 2017-04-21
FR17C1009I2 true FR17C1009I2 (fr) 2019-04-12

Family

ID=43527590

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1009C Active FR17C1009I2 (fr) 2009-07-29 2017-03-17 Agents therapeutiques pour reduire les niveaux d' hormone parathyroidienne

Country Status (30)

Country Link
US (10) US8999932B2 (fr)
EP (5) EP3539555B1 (fr)
JP (3) JP5270799B2 (fr)
KR (1) KR101781841B1 (fr)
CN (2) CN107674114B (fr)
AU (1) AU2010278897B2 (fr)
BR (1) BR112012002143B8 (fr)
CA (1) CA2769525C (fr)
CY (3) CY1118388T1 (fr)
DK (2) DK2459208T3 (fr)
ES (2) ES2729051T3 (fr)
FR (1) FR17C1009I2 (fr)
HK (1) HK1167108A1 (fr)
HR (2) HRP20161614T1 (fr)
HU (3) HUE030960T2 (fr)
IL (1) IL217749A (fr)
LT (3) LT2459208T (fr)
LU (1) LUC00008I2 (fr)
MX (1) MX2012001213A (fr)
NO (1) NO2017021I1 (fr)
NZ (1) NZ597922A (fr)
PL (2) PL3192520T3 (fr)
PT (2) PT2459208T (fr)
RU (1) RU2557654C3 (fr)
SG (2) SG10201406921SA (fr)
SI (2) SI3192520T1 (fr)
SM (1) SMT201700014B (fr)
TW (1) TWI520744B (fr)
WO (1) WO2011014707A2 (fr)
ZA (1) ZA201200726B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103961686A (zh) * 2006-11-16 2014-08-06 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
MX2012001213A (es) 2009-07-29 2012-06-12 Kai Pharmaceuticals Inc Agentes terapeuticos para reducir los niveles de la hormona paratiroidea.
HUE041362T2 (fr) 2010-03-04 2019-05-28 Ea Pharma Co Ltd
EP2543660A4 (fr) 2010-03-04 2014-04-30 Ajinomoto Kk Agent prophylactique ou thérapeutique pour le diabète ou l'obésité
WO2011118843A1 (fr) 2010-03-24 2011-09-29 味の素株式会社 Dérivés de glutamate ou sels de ceux-ci
WO2011126099A1 (fr) 2010-04-02 2011-10-13 味の素株式会社 Agent prophylactique ou thérapeutique du diabète ou de l'obésité
SI2717896T1 (sl) * 2011-06-08 2017-04-26 Kai Pharmaceuticals, Inc. Terapevtska sredstva za reguliranje serumskega fosforja
CA2854911C (fr) * 2011-11-10 2019-09-24 Kai Pharmaceuticals, Inc. Calcimimetiques et procedes pour leur utilisation
CA2870711A1 (fr) 2012-04-17 2013-10-24 Brown University Composition neuroprotectrice et methode d'utilisation
US20200354428A9 (en) 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
CN114376970A (zh) 2013-06-28 2022-04-22 美国安进公司 Etelcalcetide (AMG 416)的稳定的液体制剂
ES2786225T3 (es) 2014-04-03 2020-10-09 Amgen Inc Método para preparar AMG 416
CN105504012A (zh) * 2014-09-30 2016-04-20 深圳翰宇药业股份有限公司 一种多肽的制备方法
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
JP6783787B2 (ja) * 2015-03-26 2020-11-11 アムジェン インコーポレイテッド エテルカルセチドの調製のための液相方法
US9336841B1 (en) * 2015-04-16 2016-05-10 Taiwan Semiconductor Manufacturing Co., Ltd. Pipeline register with data alignment therein
CN106928320B (zh) 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
WO2018044468A1 (fr) * 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINAISON D'UNE FAIBLE DOSE DE 2-MÉTHYLÈNE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMINE D3 ET D'AGENTS CALCIMIMÉTIQUES POUR TRAITER UNE HYPERPARATHYROÏDIE SECONDAIRE
CN111601614A (zh) * 2017-11-07 2020-08-28 阿尔法科制药有限责任公司 治疗和预防心脏病、心血管疾病及相关病症和症状的方法
CN111386109A (zh) 2017-12-20 2020-07-07 Ea制药株式会社 维持性透析下的继发性甲状旁腺功能亢进症的预防或治疗用医药组合物
US20210369769A1 (en) * 2018-11-02 2021-12-02 Dyve Biosciences, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers
WO2020204117A1 (fr) 2019-04-03 2020-10-08 Ｅａファーマ株式会社 Composition pharmaceutique présentant une stabilité améliorée
MX2022006892A (es) * 2019-12-09 2022-10-07 Beijing Tuo Jie Biopharmaceutical Co Ltd Compuesto agonista del receptor sensor de calcio y aplicación del mismo.
US20230223125A1 (en) * 2020-05-04 2023-07-13 University Of Louisville Research Foundation, Inc. Artificial intelligence-based systems and methods for dosing of pharmacologic agents
CN115087662B (zh) * 2020-09-10 2023-09-26 陕西麦科奥特科技有限公司 双特异性融合多肽化合物
US11359134B2 (en) 2020-10-19 2022-06-14 Saudi Arabian Oil Company Treatment fluids and methods for recovering hydrocarbons from a subterranean formation
WO2022257958A1 (fr) * 2021-06-08 2022-12-15 北京拓界生物医药科技有限公司 Composition d'agoniste du récepteur de détection du calcium et son application
CN117500820A (zh) * 2021-06-08 2024-02-02 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
CA1333616C (fr) 1989-03-09 1994-12-20 Hector F. Deluca Composes de type 19-nor-vitamine d
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
AU9131091A (en) * 1990-11-07 1992-06-11 Scripps Research Institute, The Peptides that inhibit platelet binding of adhesion molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
CA2145214A1 (fr) 1995-02-28 1996-08-29 Rick E. Preddie Agents pour diagnostic pre-symptomatique, prevention et traitement de la maladie de huntington chez l'homme
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
WO1998004591A1 (fr) 1996-07-31 1998-02-05 The General Hospital Corporation Nouveaux analogues de la proteine liee a l'hormone parathyroide
US5895368A (en) 1996-09-23 1999-04-20 Medisystems Technology Corporation Blood set priming method and apparatus
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
WO1998033812A1 (fr) * 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Inhibiteurs peptidiques des proteases de mastocytes
KR100351213B1 (ko) 1997-05-14 2002-09-05 아벤티스 파마슈티칼스 인크. 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물
BR9809138A (pt) * 1997-05-21 2001-08-28 Trustees For The Leland Stanfo Conjugado e método para aumentar o transporte de um composto selecionado atravessando uma membrana biológica
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
JP2000336099A (ja) * 1999-05-27 2000-12-05 Sekisui Chem Co Ltd ペプチド及びｃ型肝炎抗体検出用試薬
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US20020068342A1 (en) * 2000-02-09 2002-06-06 Rami Khosravi Novel nucleic acid and amino acid sequences and novel variants of alternative splicing
EP2070911A2 (fr) 2000-07-18 2009-06-17 Bone Care International, Inc. 1Alpha-hydroxy vitamine D stabilisée
DE10041126A1 (de) * 2000-08-22 2002-04-04 Aventis Res & Tech Gmbh & Co DNA-bindende Peptiddomänen und ein Verfahren zur Bereitstellung solcher Domänen
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
US6855693B2 (en) 2001-01-18 2005-02-15 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of δPKC
US20030091640A1 (en) 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
US20030036627A1 (en) 2001-02-16 2003-02-20 Montelaro Ronald C. Virus derived antimicrobial peptides
JP4310106B2 (ja) 2001-02-23 2009-08-05 ポリファー リミテッド 抗菌活性を有するテンプレート結合ペプチド擬似体
WO2003013543A1 (fr) 2001-08-08 2003-02-20 Genomed, Llc Traitement ou prevention de l'insuffisance renale aigue
US6790833B2 (en) * 2001-08-08 2004-09-14 The Research Foundation Of The State University Of New York Antifungal and antibacterial agents
US7060023B2 (en) 2001-09-25 2006-06-13 The Foundry Inc. Pericardium reinforcing devices and methods of using them
JP2005287302A (ja) 2002-04-03 2005-10-20 Haruhiko Fujiwara ポリペプチドの架橋方法
US20040018976A1 (en) 2002-05-14 2004-01-29 Feder John N. Polynucleotide encoding novel human G-protein coupled receptors, and splice variants thereof
AU2004291277A1 (en) 2003-11-05 2005-06-02 Intercell Ag Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens
EP1699813A2 (fr) 2003-12-11 2006-09-13 The Board Of Trustees Of The Leland Stanford Junior University Antagonistes specifiques des isozymes contre la proteine-kinase c
WO2005072340A2 (fr) 2004-01-27 2005-08-11 Compugen Ltd. Nouveaux polynucleotides codant pour des polypeptides et leurs procedes d'utilisation
EP1781320A2 (fr) * 2004-07-27 2007-05-09 Genzyme Corporation Utilisation de thyrotropine pour la regeneration des os
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
KR100687932B1 (ko) * 2005-08-09 2007-02-27 삼성전자주식회사 영상표시장치 및 영상표시방법
CA2621167A1 (fr) 2005-08-30 2007-03-08 Acologix, Inc. Regulation du metabolisme mineral et squelettique
CN103961686A (zh) * 2006-11-16 2014-08-06 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
KR102274003B1 (ko) 2007-01-19 2021-07-08 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
CA2701274A1 (fr) 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides pour la distribution d'acides nucleiques
WO2009075773A2 (fr) 2007-12-07 2009-06-18 Goldstein Steven A Identification de ligands de toxine
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
MX2012001213A (es) 2009-07-29 2012-06-12 Kai Pharmaceuticals Inc Agentes terapeuticos para reducir los niveles de la hormona paratiroidea.
SI2717896T1 (sl) 2011-06-08 2017-04-26 Kai Pharmaceuticals, Inc. Terapevtska sredstva za reguliranje serumskega fosforja
CA2854911C (fr) 2011-11-10 2019-09-24 Kai Pharmaceuticals, Inc. Calcimimetiques et procedes pour leur utilisation

Also Published As

Publication number Publication date
IL217749A0 (en) 2012-03-29
US20200399309A1 (en) 2020-12-24
EP2459208A4 (fr) 2014-06-04
TW201116290A (en) 2011-05-16
US10280198B2 (en) 2019-05-07
SMT201700014B (it) 2017-03-08
HUE043838T2 (hu) 2019-09-30
PT2459208T (pt) 2017-01-03
EP2459208A2 (fr) 2012-06-06
CY1121922T1 (el) 2020-10-14
EP3808363B1 (fr) 2022-09-07
WO2011014707A2 (fr) 2011-02-03
PL3192520T3 (pl) 2019-08-30
CN102711789B (zh) 2018-06-08
US20160159860A1 (en) 2016-06-09
PL2459208T3 (pl) 2017-05-31
EP3192520B1 (fr) 2019-03-06
NZ597922A (en) 2015-01-30
MX2012001213A (es) 2012-06-12
BR112012002143B8 (pt) 2021-05-25
US20170114095A1 (en) 2017-04-27
PT3192520T (pt) 2019-06-12
US9567370B2 (en) 2017-02-14
RU2012107428A (ru) 2013-09-10
LUC00008I2 (fr) 2017-05-30
EP3539555A1 (fr) 2019-09-18
ZA201200726B (en) 2013-05-29
SG10201406921SA (en) 2014-11-27
CN107674114A (zh) 2018-02-09
CY2017010I1 (el) 2017-11-14
BR112012002143B1 (pt) 2020-12-08
JP5764613B2 (ja) 2015-08-19
EP3192520A1 (fr) 2017-07-19
US20240116983A1 (en) 2024-04-11
US20120178688A1 (en) 2012-07-12
US20180022777A1 (en) 2018-01-25
US20150175664A1 (en) 2015-06-25
JP5270799B2 (ja) 2013-08-21
US8999932B2 (en) 2015-04-07
US20110028394A1 (en) 2011-02-03
EP4154900A1 (fr) 2023-03-29
LTPA2017007I1 (lt) 2017-03-27
EP3808363A1 (fr) 2021-04-21
HK1167108A1 (zh) 2012-11-23
ES2729051T3 (es) 2019-10-30
HRP20161614T1 (hr) 2017-02-24
JP2014094967A (ja) 2014-05-22
CN102711789A (zh) 2012-10-03
JP2013500990A (ja) 2013-01-10
TWI520744B (zh) 2016-02-11
CA2769525A1 (fr) 2011-02-03
SI3192520T1 (sl) 2019-08-30
JP2013155195A (ja) 2013-08-15
CA2769525C (fr) 2017-02-21
BR112012002143A2 (pt) 2016-11-08
LT2459208T (lt) 2017-02-27
KR20120104513A (ko) 2012-09-21
EP3539555B1 (fr) 2020-12-30
AU2010278897B2 (en) 2015-02-26
IL217749A (en) 2016-09-29
HUS1700008I1 (hu) 2017-04-28
LTC2459208I2 (lt) 2021-07-12
SG178143A1 (en) 2012-03-29
RU2557654C2 (ru) 2015-07-27
US20190194252A1 (en) 2019-06-27
RU2557654C3 (ru) 2017-07-05
US9701712B2 (en) 2017-07-11
LT3192520T (lt) 2019-06-25
NO2017021I1 (no) 2017-05-05
AU2010278897A1 (en) 2012-02-23
US9278995B2 (en) 2016-03-08
LUC00008I1 (fr) 2017-03-16
CN107674114B (zh) 2022-10-25
HUE030960T2 (en) 2017-06-28
CY1118388T1 (el) 2017-06-28
DK2459208T3 (en) 2017-01-23
KR101781841B1 (ko) 2017-09-26
DK3192520T3 (da) 2019-05-27
SI2459208T1 (sl) 2017-04-26
ES2607954T3 (es) 2017-04-04
US8377880B2 (en) 2013-02-19
EP2459208B1 (fr) 2016-09-28
US20130150297A1 (en) 2013-06-13
CY2017010I2 (el) 2017-11-14
HRP20190923T1 (hr) 2019-10-04
WO2011014707A3 (fr) 2011-07-07
FR17C1009I1 (fr) 2017-04-21

Similar Documents

Publication Publication Date Title
FR17C1009I2 (fr) Agents therapeutiques pour reduire les niveaux d' hormone parathyroidienne
FR2949669B1 (fr) Mecanisme d'epaule pour orthese
BRPI1012004A2 (pt) "forma farmacêutica"
FR2954857B3 (fr) Accumulateur ion-lithium specifique pour l'allumage de motos
BR112012002519A2 (pt) "pesticidas mesoiônicos"
BR112012010595A2 (pt) "dispensdor"
BR112012004546A2 (pt) "terapêutica por proteínas ligantes dll4-ligantes"
IT1395915B1 (it) Potabilizzatore d'acqua
GB0921075D0 (en) Novel combination of the therapeutic agents
BRPI1013001A2 (pt) "bioprocessamento"
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"
IT1393777B1 (it) Composizione per l'igiene intima
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
SMT201600041B (it) Agenti terapeutici 713
FR2960418B1 (fr) Ensemble glenoidien pour prothese d'epaule
BRPI1009730A2 (pt) "recipiente"
PL2559662T3 (pl) Dzbanek do filtrowania wody
SMT201600224B (it) Trattamento dell'osteoporosi
IT1397522B1 (it) Uso di una combinazione per il trattamento dell'osteoartrosi
ITRM20090640A1 (it) "swimming goggle structure"
BRPI1012632A2 (pt) "misturador vedado"
ES1070436Y (es) "masajeador corporal"
BRPI1013017A2 (pt) "17beta-alquil-17alfa-óxi-estratrienos"
FR2922241B1 (fr) Piscine pour la natation
IT1404355B1 (it) " occhiali per nuoto " .